Full text is available at the source.
Hepatic STAMP2 mediates recombinant FGF21‐induced improvement of hepatic iron overload in nonalcoholic fatty liver disease
Liver STAMP2 helps FGF21 reduce iron buildup in fatty liver disease
AI simplified
Abstract
Recombinant FGF21 treatment improved hepatic steatosis and insulin resistance through the upregulation of STAMP2 expression.
- FGF21 administration may reverse liver fat accumulation in nonalcoholic fatty liver disease (NAFLD).
- STAMP2 expression is associated with the therapeutic effects of FGF21 on NAFLD.
- Human NAFLD patient samples and mouse models showed signs of hepatic iron overload and decreased ferroportin expression.
- FGF21 may enhance iron export from the liver by increasing ferroportin levels via STAMP2.
- STAMP2 could serve as a potential target for therapeutic interventions in FGF21-related NAFLD treatment.
AI simplified